Baseline histologic activity predicted colectomy risk in ulcerative colitis treated with biologics, independent of clinical or endoscopic factors.
The FDA has approved 2 additional vial sizes of Niktimvo™ (axatilimab-csfr), 9mg/0.18mL and 22mg/0.44mL, in addition to the 50mg/mL size.
Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel ...
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
The findings suggest that lipid composition can direct mRNA-based drugs to target organs, such as the intestines, without passing through the liver.
Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating ...
Inc. (NYSE American: PTN), a small-cap biotech company with a market capitalization of $20.4 million, has announced its corporate milestones for 2025, focusing on the development of treatments for ...
The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...
Many with Crohn’s disease or ulcerative colitis sacrifice essential purchases like food and clothing for healthcare, survey ...
Crohn’s disease and ulcerative colitis (UC) are both types of inflammatory bowel disease (IBD) that share similar symptoms but differ in their affected areas, disease progression, and treatment ...
This is a confusing and controversial topic in IBD, with broad implications for treatment. It's estimated that between 10% and 15% of people with IBD are thought to have indeterminate colitis. In some ...
Many choose IPL because it can provide the desired results with minimal pain and downtime. However, when compared to other skin rejuvenation treatments, IPL may require more sessions to achieve the ...